In clinical trials involving people with type 2 diabetes, Mounjaro led to significant weight loss
It is a 31-amino-acid linear peptide engineered with targeted substitutions and a C18 fatty diacid side chain conjugated to the -amino group of Lys26 , a modification studied for its role in enhancing metabolic stability and prolonging systemic persistence in research models
For the once-weekly subcutaneous formulation, the SUSTAIN program (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) included 13 separate randomized clinical phase 3a and 3b trials ( Table 1 Overview of Phase 3 studies of oral semaglutide (PIONEER) and subcutaneous semaglutide (SUSTAIN) ( *Phase 3b trials all others are phase 3a trials CKD, chronic kidney disease
Recently, there have been notable progress in the field of metabolic diseases, particularly in the demonstrated therapeutic potential of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists [8]
Switching to a smaller gauge needle to inject means less pain and not using the needle more than once
As Clinical Pharmacists, we play a vital role in safeguarding patients by ensuring the right medicine reaches the right patient through a secure and reliable supply chain
